Background It is not well-known to what extent evidence-based medications, such as β-
blockers, hypolipidemic medications, and angiotensin-converting enzyme inhibitors, are …

Guidelines recommend long-term use of beta-blockers (BB), statins, and angiotensin-
converting-enzyme-inhibitors or angiotensin-receptor-blockers (ACEI/ARB) after myocardial …

Purpose The recommended pharmacotherapy for secondary prevention of acute coronary
syndrome (ACS) is long-term treatment with a combination of four therapeutic classes: beta …

Background Secondary preventive drug therapy following acute myocardial infarction (AMI)
is recommended to reduce the risk of new cardiovascular events. The aim of this nationwide …

Background The prescription of guideline-recommended medication for secondary
prevention after acute coronary syndrome has been suboptimal in the past. In the present …

Objective: To examine temporal trends in hospital use of secondary preventive medicine
after discharge for first acute myocardial infarction (AMI) in Denmark. Design: Observational …

The use of cardiovascular secondary prevention medications in patients with acute coronary
syndromes was compared in 4 sequential observational surveys carried out in France from …

Purpose Myocardial infarction (MI) survivors benefit from receiving secondary prevention,
including beta‐blockers, angiotensin‐blocking agents, and statins, as recommended by …

Background: There is evidence that several classes of drugs are beneficial for secondary
prevention in patients with coronary artery disease. Objective: To compare the use of …

Objective To ascertain the use of secondary prevention medications and cardiac
rehabilitation after an acute coronary syndrome (ACS) and the impact on 2-year outcomes …